In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Potentially inappropriate medication use in elderly patients with heart failure: beers criteria-based review

Session Poster Session 3

Speaker Mariam Zahwe

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : M Zahwe (Beirut,LB), H Skouri (Beirut,LB), A Al-Hajje (Beirut,LB), H Tamim (Beirut,LB), S Rachidi (Beirut,LB), H Isma'eel (Beirut,LB)

M Zahwe1 , H Skouri2 , A Al-Hajje1 , H Tamim2 , S Rachidi1 , H Isma'eel2 , 1Lebanese University - Beirut - Lebanon , 2American University of Beirut Medical Center - Beirut - Lebanon ,


Background: Elderly heart failure (HF) patients are considered among the highest consumers of drugs. Their complex drug regimens and various comorbidities predispose them to inappropriate prescribing of medications. "Beers criteria" is among the most widely used criteria for the evaluation of potentially inappropriate medications (PIMs) use in elderly patients. 
Purposes: The aim of this study is to evaluate the proportion of PIMs in elderly HF patients as well as the factors associated with the number of PIMs. Also, to test for the correlation between PIMs and the impairment in quality of life and depression in this vulnerable population.  
Methods: This study is using an observational cross-sectional design, targeting 120 consecutive HF outpatients =65 years, with ejection fraction <50%, who are being recruited from a tertiary care center. Patients with history of acute coronary event in the preceding 3 months and patients with severe cognitive impairments are excluded. Data for medications, doses, clinical data, and demographics are collected at discharge from the clinic. Patient is interviewed with the Minnesota Living with Heart Failure Questionnaire (MLHFQ) for measuring quality of life and the patient health questionnaire (PHQ9) for depression. Data are then evaluated for the use of PIMs using the updated Beer’s criteria 2015. 
Results: In total, 74.8% of our sample are males, 58.9% are young-old patients (65-74 years), and 68.2% had a history of hypertension. The total number of medications taken by our sample is 924 with an average of 8.64±2.82 medication per prescription. Preliminary results showed that the percentage of patients receiving at least one PIM is 80.4%, with an average of 1.70 ± 1.26 PIM per prescription, and 29.0% of HF patients are having 2 PIM in their prescription. Most of the PIMs are from the category of medications to use with caution (63.6%) and to be avoided in many or most older adults (53.3%). Diuretics (57.0%), proton pump inhibitors (41.1%), aspirin (14.0%), and benzodiazepines (9.3%) are the most commonly prescribed PIMs. Significant correlation is found between number of PIMs per patient with the MLHFQ score (pearson's coefficient r= 0.28, p=0.003), PHQ9 score (r=0.23, p=0.017), and number of medications per prescription (r=0.49, p<0.001). Multivariate Linear regression showed a significant association between the number of PIMs per prescription with the number of medications (regression coefficient beta=0.190, p<0.001), oldest-old age (beta=1.136, p=0.006), and having a chronic kidney disease (beta=0.588, p=0.031). 
Conclusions: Elderly HF patients are having a high percentage of PIMs. An excessive unnecessary use of proton pump inhibitors is observed in this population. The PIMs are affecting negatively the quality of life of HF patients and associated with more depression. There is a need for a multidisciplinary team to help in controlling the prescription of PIMs in this vulnerable population.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are